Background {#s0005}
==========

Since the detection of carcinoembryonic antigen (CEA) in 1965 [@bb0005] a large number of biomarker candidates have been proposed to have a potential prognostic impact in colorectal cancer (CRC). However, CEA is still the only serologic marker recommended in surveillance for CRC by experts groups of American society of colon and rectal surgeons [@bb0010] and European society for medical oncology [@bb0015].

Due to the lack of sensitivity or specificity of the biomarker candidates and due to the polymorphism of the CRC and the tested cohorts none of the suggested biomarker candidates have shown superiority to CEA. The field is extensively expanding due to new analytic techniques such as next generation sequencing, which adds to the complexity of the information.

The present cohort has previously been used for several studies that have improved our understanding on both soluble and tissue prognostic biomarkers [@bb0020], [@bb0025], [@bb0030], [@bb0035], [@bb0040], [@bb0045], [@bb0050], [@bb0055], [@bb0060], [@bb0065], [@bb0070]. In this study, in search for prognostic biomarkers, the samples were assessed using the proximity extension assays (PEA) [@bb0075], [@bb0080], and a protein panel consisting of 92 highly oncology-related protein biomarker candidates. In the multiplex PEA, each target protein is recognized by a pair of DNA-conjugated affinity binders such as poly- and monoclonal antibodies. Upon simultaneous target recognition the DNA arms on the antibodies are brought in proximity and hybridized to each other allowing an enzymatic DNA polymerization. The newly synthesized DNA molecule is then amplified using real-time qPCR. A combination of duel recognition and subsequent signal amplification results in detection of proteins with high specificity and sensitivity. The technology has now been widely used and is demonstrated to be suitable for multiplex and high throughput analyses of panels of proteins in large numbers of samples. The technology has, for instance, been used to identify novel biomarker candidates for small intestinal neuroendocrine tumor [@bb0085] to demonstrate the strong effect of genetic and lifestyle factors on protein biomarker levels [@bb0090] to identify circulating protein markers predicting of incident heart failure in the elderly [@bb0095] to reveal lower levels of several peripheral inflammatory protein biomarkers in women with antenatal depression [@bb0100]. The PEA has also been used to characterize exosomal proteome and to trace the exosomes to their originating cells and tissues [@bb0105].

The aim of this study was to investigate whether any of the selected biomarker candidates allow prediction of death or disease recurrence in patients with CRC.

Materials and Methods {#s0010}
=====================

Patient Samples {#s0015}
---------------

The study was prospective and the cohort included patients treated for CRC at the Department of Surgery, Central District Hospital, Västerås, County of Västmanland, Sweden, with a population of 260,000. The study period was between August 2000 and December 2003, and the inclusion criterion was a histologically verified adenocarcinoma of the rectum or colon. The total number of this patients cohort is 324, but for the present study samples from a subgroup of 270 patients were analyzed with disease stages II-IV, excluding disease stage I due to good prognosis with only one recurrence in that group.

Blood samples were collected into endotoxin-free tubes with EDTA one day prior to the planned resection of the CRC. For plasma preparation, the blood samples were centrifuged at 2,000×*g* for 10 min at room temperature, and plasma was transferred to a new tube and stored at −70°C until use. All assays were performed in a blinded manner.

Surveillance was according to national guidelines with computed tomography scan of thorax and abdomen after 1 and 3 years, and colonoscopy every 5 years up to 75 years of age for all patients. Patients with rectal cancer underwent rectoscopy or palpation of perineum every 6 months up to 3 years and then after 4 and 5 years from the operation. Additional radiological examinations outside the surveillance program were made if patients sought with symptoms suspecting recurrence of the CRC.

Information about disease stage, tumor differentiation grade, mucinous histology, death and cancer recurrence were collected from the histopathological, surgical and oncology records.

The latest update on the database was in May 2015 with new recurrences and the exact date of deaths recorded, which were available from the computerized hospital record system.

Protein detection {#s0020}
-----------------

The PEA was performed using Olink Oncology I panel (Olink Proteomics, Uppsala, Sweden), according to the manufacturer\'s instructions and as described previously [@bb0075], [@bb0105]. The list of the 92 oncology-related proteins included in the panel is summarized in [Table 1](#t0005){ref-type="table"}. Briefly, 1 μl plasma sample was mixed with 3 μl incubation mix, containing a mixture of 92 probe pairs, in a 96-well plate. Each probe consisting of an antibody conjugated to a unique DNA oligonucleotide. The mixture was incubated at 4°C overnight, allowing recognition of target proteins by a pair of probes. Thereafter, 96 μl extension mix, containing PEA enzyme and PCR reagents, was added, the mixture was incubated for 5 min at room temperature before the DNA extension was initiated in a thermal cycler for 20 min at 50°C, followed by 17 cycles DNA amplification. A new mixture was prepared by adding 2.8 μl of the PCR products to 7.2 μl detection mix in a new 96-well plate from which 5 μl was transferred to a 96.96 Dynamic Array IFC (Fluidigm, South San Francisco, CA, USA) that was in advanced prepared and primed according to the manufacturer\'s instructions. The unique pair of primers for each protein was loaded in the other side of the array chip and the expression program was performed in a BioMark™ HD real-time PCR platform (Fluidigm, South San Francisco, CA, USA).Table 1Proteins included in the Olink Oncology I panel sorted according to the short name and with the UniProt number given for identificationTable 1Long nameShort nameUniProtIncluded in data analysisAgeGenderDisease stageDifferentiation gradeMucinous histologyCEAAdrenomedullinAMP35318Yes**3,49E-20**0,926170,727350,028730,672770,00334AmphiregulinARP15514Yes**3,391E-06**0,922260,115280,218120,210960,00248B-cell activating factorBAFFQ9Y275Yes0,910830,060510,076100,057330,121100,53705BetacellulinBTCP35070NoOvarian cancer-related tumor marker CA 125CA-125Q8WXI7NoCA242 tumor markerCA242NANoCarbonic anhydrase IXCAIXQ16790Yes0,000690,475160,974100,944440,026900,00458Caspase-3CASP-3P42574Yes0,565270,187860,001280,051530,198240,00241C-C motif chemokine 19CCL19Q99731Yes0,050490,346100,879580,080080,806370,06273C-C motif chemokine 21CCL21O00585Yes0,280630,002660,145950,831410,987150,00850C-C motif chemokine 24CCL24O00175Yes0,965780,552730,015970,769780,363900,02977Tumor necrosis factor ligand superfamily member 8CD30-LP32971Yes0,268500,351140,978880,465160,526760,96319CD40 ligandCD40-LP29965Yes0,836070,013420,005820,525380,115690,19351Early activation antigen CD69CD69Q07108Yes0,008180,300360,007410,093380,004260,00250Carcinoembryonic antigenCEAP06731Yes0,540550,778590,000120,482810,00109**7,33E-102**Macrophage colony-stimulating factor 1CSF-1P09603Yes0,000220,889120,572050,008160,138550,00108Cystatin-BCSTBP04080Yes**7,886E-22**0,880720,655410,169400,553410,00162Cathepsin DCTSDP07339Yes0,000930,384290,072730,086700,09496**7,252E-07**C-X-C motif chemokine 10CXCL10P02778Yes**2,334E-10**0,142830,781540,663200,834100,48876C-X-C motif chemokine 11CXCL11O14625Yes0,001610,043330,008870,280020,084730,30461C-X-C motif chemokine 13CXCL13O43927Yes**1,081E-09**0,468520,912030,121930,037680,06175C-X-C motif chemokine 5CXCL5P42830Yes0,708730,247600,371770,539570,796580,24615C-X-C motif chemokine 9CXCL9Q07325Yes**8,542E-21**0,565410,549380,089080,541160,16928Epidermal growth factorEGFP01133Yes0,545900,277620,001900,674670,015910,19299Epidermal growth factor receptorEGFRP00533Yes**1,406E-10**0,990190,602450,533770,674440,10562Extracellular matrix metalloproteinase inducerEMMPRINP35613Yes0,000340,177810,665860,544660,671870,00862Epithelial cell adhesion moleculeEp-CAMP16422Yes0,443070,936600,013920,536790,827820,30788ErythropoietinEPOP01588NoEpiregulinEPRO14944NoEstrogen receptorERP03372NoReceptor tyrosine-protein kinase erbB-2ErbB2/HER2P04626Yes0,039410,249250,376030,514450,503720,08963Receptor tyrosine-protein kinase erbB-3ErbB3/HER3P21860Yes**8,384E-05**0,000660,000690,805210,148310,21119Receptor tyrosine-protein kinase erbB-4ErbB4/HER4Q15303Yes0,828190,831790,418700,951640,765640,33745Fatty acid-binding protein, adipocyteFABP4P15090Yes**3,774E-091,788E-11**0,280340,090660,955030,13437Tumor necrosis factor receptor superfamily member 6FASP25445Yes**3,84047E-14**0,090230,010820,486240,256980,47818Fas antigen ligandFasLP48023Yes0,555690,592870,842960,618880,988060,40235Fms-related tyrosine kinase 3 ligandFlt3LP49771Yes0,242820,616350,772040,187780,260380,15515Folate receptor alphaFR-alphaP15328Yes**1,014E-19**0,430650,012880,209130,923900,26595FollistatinFSP19883Yes**1,985E-05**0,160600,984450,219990,923900,05947Galectin-3Gal-3P17931Yes0,007760,010150,010830,31,9960,064240,03338Growth/differentiation factor 15GDF-15Q99988Yes**8,473E-10**0,710910,034530,163520,83770**7,016E-05**Growth hormoneGHP01241Yes0,011590,008610,484150,080310,027630,03192Granulocyte-macrophage colony-stimulating factorGM-CSFP04141NoGranulocyte-macrophage colony-stimulating factorHB-EGFQ99075Yes0,508410,073160,042360,202700,569680,44013Epididymal secretory protein E4HE4Q14508Yes**3,383E-31**0,011520,107850,051110,881070,00674Hepatocyte growth factorHGFP14210Yes0,000290,762830,063890,069630,421150,00022Hepatocyte growth factor receptorHGF receptorP08581Yes0,502380,696150,881640,149700,901950,83913Kallikrein-11hK11Q9UBX7Yes**9,316E-18**0,005430,056900,126810,257840,01238Interferon gammaIFN-gammaP01579NoInterferon gammaIL-12P29459/60Yes**7,216E-05**0,139060,915340,208970,522280,35490Interleukin-17 receptor BIL-17RBQ9NRM6Yes0,011130,033490,222250,379110,267200,49359Interleukin-1 receptor antagonist proteinIL-1raP18510Yes0,047250,000190,016060,407750,335600,01576Interleukin-2IL-2P60568NoInterleukin-2 receptor subunit alphaIL-2RAP01589Yes0,000380,096290,428060,305460,820640,07836Interleukin-4IL-4P05112NoInterleukin-6IL-6P05231Yes**9,415E-05**0,514470,057940,057140,029890,00011Interleukin-6 receptor subunit alphaIL-6RAP08887Yes0,224980,540160,53,0420,351890,254080,78588Interleukin-7IL-7P13232Yes0,799120,510260,259510,595130,238850,82102Interleukin-8IL-8P10145Yes0,001250,165310,047710,137960,219060,00182Kallikrein-6KLK6Q92876Yes**4,571E-06**0,018640,761240,628310,511840,17768Latency-associated peptide transforming growth factor beta-1LAP TGF-beta-1P01137Yes**3,993E-05**0,863920,025840,325980,971540,01379Monocyte chemotactic protein 1MCP-1P13500Yes**0,000105**0,319480,723520,772930,902910,10979Melanoma-derived growth regulatory proteinMIAQ16674Yes0,000410,039880,636450,453240,283980,54626MHC class I polypeptide-related sequence AMIC-AQ29983Yes0,888350,276500,035130,513660,117230,01091MidkineMKP21741Yes**2,672E-07**0,352420,047090,145050,163430,00024Matrix metalloproteinase-3MMP-3P08254NoMyeloperoxidaseMPOP05164Yes0,015910,634930,093270,326170,029620,02671Myeloid differentiation primary response protein MyD88MYD88Q99836NoOsteoprotegerinOPGO00300Yes**8,566E-23**0,147800,454340,264130,594150,00043Platelet-derived growth factor subunit BPDGF subunit BP01127Yes0,495820,256430,056850,507560,384310,62864Platelet endothelial cell adhesion moleculePECAM-1P16284Yes0,044890,945080,274460,463610,586990,00061Placenta growth factorPlGFP49763Yes**1,141E-18**0,002590,845110,775970,787700,00105ProlactinPRLP01236Yes0,409480,325920,042990,083770,173760,80941ProstasinPRSS8Q16651Yes0,00048**2,256E-07**0,513640,925480,511100,00264Prostate-specific antigenPSAP07288NoRegenerating islet-derived protein 4REG-4Q9BYZ8Yes**4,921E-09**1,000000,628310,235091**,567E-05**0,00011Stem cell factorSCFP21583Yes0,099930,309240,175740,752120,260380,00033E-selectinSELEP16581Yes0,002090,148240,031260,271680,15854**1,115E-06**Tissue factorTFP13726Yes**2,509E-14**0,153610,031130,762050,739440,19597Transforming growth factor alphaTGF-alphaP01135Yes**2,505E-09**0,672180,253090,255370,719540,00038ThrombopoietinTHPOP40225Yes0,778740,033330,029020,307370,261820,93534Angiopoietin-1 receptorTIE2Q02763Yes0,001380,880710,020180,808730,014050,00014Tumor necrosis factorTNFP01375NoTumor necrosis factor receptor 1TNF-R1P19438Yes**3,664E-16**0,134510,912120,073030,288130,00135Tumor necrosis factor receptor 2TNF-R2P20333Yes**2,425E-14**0,115010,922490,053060,703270,00435Tumor necrosis factor receptor superfamily member 4TNFRSF4P43489Yes**2,411E-10**0,335790,303760,227750,913490,00018Tumor necrosis factor ligand superfamily member 14TNFSF14O43557Yes0,185750,033360,377110,109510,028420,00022Tartrate-resistant acid phosphatase type 5TR-APP13686Yes0,326650,000920,006530,419620,199030,06662Urokinase plasminogen activator surface receptorU-PARQ03405Yes**1,330E-16**0,348170,653820,030480,20760**1,088E-05**Vascular endothelial growth factor AVEGF-AP15692Yes**3,727E-09**0,736710,347510,063100,487700,00288Vascular endothelial growth factor DVEGF-DO43915Yes0,988370,172660,991520,436260,427160,98259Vascular endothelial growth factor receptor 2VEGFR-2P35968Yes**9,449E-06**0,133420,870550,733030,384260,66257[^1]

The CEA determination was on serum with a commercially available ELISA kit. The analysis is based on the principle of a Solid-Phase-Enzyme-Linked immunosorbent assay. According to the manufacturer\'s instructions, this assay has a detection limit of 1 ng/ml and the standard range is 5 to 75 ng/ml. (IBL; Immuno Biological Laboratories; http://www.ibl-hamburg.com).

The study was approved by the Regional Ethics Committee in Uppsala, Sweden (Dnr. 2000:001 and Dnr. 2009:345). Written study information was given to the patients, and all patients participating in the study gave a verbal consent. The verbal consent was approved by the ethical committee, and was documented in a questionnaire filled in by the patient or the researcher.

Statistical Analyses {#s0025}
====================

Of the 92 measured proteins, the 78 proteins with less than 20% of the measured values below limit of detection (LOD) were included in the data analyses ([Table 1](#t0005){ref-type="table"}).

Values for CEA measured using the ELISA kit were log-transformed before analysis. To avoid log of zero the transform log~2~ (CEA+ 1) was used.

The association between biomarkers and clinical parameters were measured univariately using Mann--Whitney test (gender, mucinous) or Spearman\'s correlation test (age, disease stage, tumor differentiation grade and CEA levels).

The association between levels of proteins and overall survival or time to recurrence was studied using Cox regression. For each protein a univariate Cox model is performed and summarized using the hazard ratio (HR) with 95% confidence interval and p-value. In addition, multivariate models with both protein level and clinical parameters as independent variable are computed and the association between survival/recurrence and protein level, adjusted for clinical parameters is assessed using the likelihood ratio test (p.lr). The clinical parameters included in the models are age and disease stage for the outcome overall survival and only disease stage for time to recurrence. Bonferroni\'s method for multiple testing correction was applied.

The recurrence or survival was illustrated with Kaplan--Meier curves, where the patients were divided into two groups with high or low protein levels using the median biomarker level as cut-off.

To investigate whether combination of more than one protein biomarker candidate did increase the prognostic significance, the most promising proteins were combined in a Cox regression model and a permutation test was adopted to check if the achieved association was stronger than expected by random.

Overall survival was measured from the date of surgery to the date of death from all causes. Time to recurrence was measured for disease stage II and III, from the date of surgery to the date of diagnosis of distant recurrence or to the date of death due to CRC, and censored at the date of death due to reasons other than CRC or at the last follow up. A second primary CRC/non-CRC was not regarded as a recurrence.

Results {#s0030}
=======

Patient Characteristics {#s0035}
-----------------------

Of the 270 patients included in this study, samples from 9 patients were excluded due to low sample quality or technical reasons. The remaining 261 samples consisted of samples from 130 females and 131 males, with a median age of 70.5 (range 34--95) years. The cohort composed of 181 colonic and 80 rectal cancer patients. Disease stage II accounted for 127 cases, while 92 were stage III and 42 stage IV. The median follow-up time of surviving patients were 13 years (range 11.5--14.8) for which disease recurrences were observed for 18 patients with stage II (14%) and 39 patients with stage III (42%). Total of 173 patients were deceased (66%).

Protein detection {#s0040}
-----------------

Samples were assessed for 92 proteins using the Multiplex Olink Oncology I panel ([Table 1](#t0005){ref-type="table"}). There were no missing values for 68 proteins and 10 proteins had less than 20% missing values due to non-detectable levels of the proteins. These 78 proteins were used for further bio-statistical analyses, while the 14 proteins with higher missing value percentages were excluded from the analyses ([Table 1](#t0005){ref-type="table"}).

Association between the protein biomarker candidates, the clinical parameters and CEA {#s0045}
-------------------------------------------------------------------------------------

In these comparisons the number of tests performed were 78\*6 = 468, hence the significance threshold was set to *P* = .05/468 = .000107 according to Bonferroni\'s method.

Statistical significant association with age was observed for 32 proteins, while two proteins were associated with gender ([Table 1](#t0005){ref-type="table"}). One protein was found to be associated with mucinous histology, and five proteins with CEA levels. No protein was found to be associated with disease stage or tumor differentiation grade ([Table 1](#t0005){ref-type="table"}).

The CEA levels measured with PEA in this study had a strong correlation with the CEA value measured earlier using ELISA ([Figure 1](#f0005){ref-type="fig"}).Figure 1Comparison of carcinoembryonic antigen (CEA) measurements performed with conventional Solid-Phase-Enzyme-Linked immunosorbent assay (ELISA)(y-axis) compared to proximity extension assay (PEA) (x-axis).Figure 1

Association Between the Protein Levels and Overall Survival {#s0050}
-----------------------------------------------------------

With 78 proteins analyzed, the p-value threshold after multiple testing correction was set to 0.05/78 = 0.000641 (calculated based on Bonferroni\'s method). According to univariate Cox regression, 31 proteins were significantly associated with overall survival ([Table 2](#t0010){ref-type="table"}). However, when the likelihood ratio *P*-value (p.lr) was calculated for overall survival, adjusting for age and disease stage, only one marker, osteoprotegerin, met the significance threshold (p.lr = .00029; [Table 2](#t0010){ref-type="table"}). See also separate Kaplan--Meier survival analysis on osteoprotegerin for disease stages II, III and IV ([Figure 2](#f0010){ref-type="fig"}, *A*--*C*).Figure 2Kaplan Meier curves for osteoprotegerin representing overall survival in disease stages II-IV using the median value of the protein levels as the cut-off between the high and low groups. (A) Osteoprotegerin disease stage II. (B) Osteoprotegerin disease stage III. (C) Osteoprotegerin disease stage IV.Figure 2Table 2Association of proteins levels with overall survival in patients with colorectal cancer (n = 261)Table 2Long nameShort nameHRl95u95pp.lrAdrenomedullinAM2.591.873.61**1.491E-08**0.0111AmphiregulinAR1.491.281.73**3.964E-07**0.1812B-cell activating factorBAFF1.320.921.900.129700.2739Carbonic anhydrase IXCAIX1.190.981.430.072420.3842Caspase-3CASP-31.080.931.240.310130.9988C-C motif chemokine 19CCL191.181.001.400.057000.3188C-C motif chemokine 21CCL211.110.701.770.649480.4311C-C motif chemokine 24CCL241.120.941.330.208400.8201Tumor necrosis factor ligand superfamily member 8CD30-L1.160.771.760.472280.6606CD40 ligandCD40-L1.181.011.370.034200.1227Early activation antigen CD69CD691.231.031.470.022660.4955Carcinoembryonic antigenCEA1.261.141.40**1.16332E-05**0.0082Macrophage colony-stimulating factor 1CSF-12.551.494.35**0.00062**0.0101Cystatin-BCSTB1.861.512.29**4.80892E-09**0.1298Cathepsin DCTSD1.421.191.70**9.35197E-05**0.1091C-X-C motif chemokine 10CXCL101.281.111.47**0.00049**0.3855C-X-C motif chemokine 11CXCL111.231.061.420.007770.6960C-X-C motif chemokine 13CXCL131.241.061.450.005940.5174C-X-C motif chemokine 5CXCL51.000.851.160.962490.7264C-X-C motif chemokine 9CXCL91.331.151.55**0.00018**0.9816Epidermal growth factorEGF1.060.921.220.446180.8578Epidermal growth factor receptorEGFR0.230.140.39**2.84429E-08**0.0028Extracellular matrix metalloproteinase inducerEMMPRIN2.581.265.270.009200.2932Epithelial cell adhesion moleculeEp-CAM1.080.941.250.266430.7436Receptor tyrosine-protein kinase erbB-2ErbB2/HER20.940.581.520.803360.5156Receptor tyrosine-protein kinase erbB-3ErbB3/HER30.730.391.370.327560.3980Receptor tyrosine-protein kinase erbB-4ErbB4/HER40.960.571.610.868940.7498Fatty acid-binding protein. AdipocyteFABP41.491.251.79**9.48259E-06**0.0288Tumor necrosis factor receptor superfamily member 6FAS1.301.051.620.017680.3298Fas antigen ligandFasL0.940.571.540.800330.6045Fms-related tyrosine kinase 3 ligandFlt3L1.060.801.400.677980.9860Folate receptor alphaFR-alpha2.521.603.95**6.11404E-05**0.2137FollistatinFS1.801.262.580.001350.1898Galectin-3Gal-32.121.463.08**7.24835E-05**0.1979Growth differentiation factor 15GDF-151.421.261.60**1.16265E-08**0.0207Growth hormoneGH1.161.071.26**0.00028**0.0137Granulocyte-macrophage colony-stimulating factorHB-EGF1.310.931.840.120020.3826Epididymal secretory protein E4HE42.772.053.75**2.90167E-11**0.0035Hepatocyte growth factorHGF1.861.452.39**1.07096E-06**0.0021Hepatocyte growth factor receptorHGF receptor0.820.223.110.771060.9033Kallikrein-11hK111.921.432.58**1.59062E-05**0.1055Interferon gammaIL-121.130.931.370.231440.4726Interleukin-17 receptor BIL-17RB1.461.091.960.011530.0107Interleukin-1 receptor antagonist proteinIL-1ra1.391.111.720.003340.1613Interleukin-2 receptor subunit alphaIL-2RA2.111.163.840.014630.3790Interleukin-6IL-61.291.161.44**2.62106E-06**0.0225Interleukin-6 receptor subunit alphaIL-6RA0.950.651.380.771940.0977Interleukin-7IL-70.830.531.290.399810.2682Interleukin-8IL-81.141.031.280.015060.0803Kallikrein-6KLK61.901.292.790.001150.1824Latency-associated peptide transforming growth factor beta-1LAP TGF-beta-13.612.175.99**6.90076E-07**0.0052Monocyte chemotactic protein 1MCP-11.551.192.010.000970.0080Melanoma-derived growth regulatory proteinMIA1.220.811.840.337980.1350MHC class I polypeptide-related sequence AMIC-A1.371.051.780.020550.1309MidkineMK1.491.241.79**1.75876E-05**0.0171MyeloperoxidaseMPO1.471.062.030.019920.8639OsteoprotegerinOPG3.332.384.66**1.84908E-120.0003**Platelet-derived growth factor subunit BPDGF subunit B1.070.911.250.416750.5598Platelet endothelial cell adhesion moleculePECAM-11.430.992.050.056740.3641Placenta growth factorPlGF2.401.753.30**6.24302E-08**0.1707ProlactinPRL1.100.911.320.332650.5899ProstasinPRSS81.971.382.82**0.00020**0.0271Regenerating islet-derived protein 4REG-41.511.221.86**0.00014**0.0129Stem cell factorSCF0.880.691.130.313500.0831E-selectinSELE1.080.901.310.406440.2589Tissue factorTF2.361.603.49**1.51693E-05**0.0349Transforming growth factor alphaTGF-alpha1.941.432.61**1.58735E-05**0.0417ThrombopoietinTHPO1.300.852.000.230540.5644Angiopoietin-1 receptorTIE21.130.651.980.658630.2310Tumor necrosis factor receptor 1TNF-R12.401.733.33**1.68115E-07**0.0153Tumor necrosis factor receptor 2TNF-R21.931.502.48**3.01838E-07**0.0263Tumor necrosis factor receptor superfamily member 4TNFRSF42.231.563.17**9.16646E-06**0.0970Tumor necrosis factor ligand superfamily member 14TNFSF141.200.941.520.146580.1851Tartrate-resistant acid phosphatase type 5TR-AP1.360.941.990.106260.8858Urokinase plasminogen activator surface receptorU-PAR4.662.907.49**1.9837E-10**0.0007Vascular endothelial growth factor AVEGF-A2.461.763.45**1.72093E-07**0.0169Vascular endothelial growth factor DVEGF-D1.300.891.920.178110.1677Vascular endothelial growth factor receptor 2VEGFR-20.480.260.900.021910.5169[^2]

Seven other proteins could be found to have a trend for association with overall survival defined as p.lr \< .01 ([Table 2](#t0010){ref-type="table"}).

Combinations of biomarkers according to the description written in material and methods did not result in improved overall survival prediction (data not shown).

Association Between the Protein Levels and Time to Recurrence {#s0055}
-------------------------------------------------------------

No statistical significant associations were observed between the levels of the 78 proteins analyzed and the time to recurrence with univariate Cox regression, when the significance threshold was set to 0.05/78 = 0.000641 (Bonferroni). However, eight proteins with p.lr \< .05 in both disease stage II and III, or separately in disease stage II or III, revealed a trend in the association with time to recurrence ([Table 3](#t0015){ref-type="table"}).Table 3Association of protein levels with time to recurrence in patients with colorectal cancerTable 3HRl95u95pp.lrDisease stage II and IIIEGFR0.430.181.030.0590.020GDF-151.351.081.690.0080.021MIC-A1.570.962.540.0700.037CXCL100.770.561.040.0910.039IL-61.241.021.500.0310.047SCF0.720.471.090.1200.050FABP41.411.031.910.0300.090HGF receptor0.150.011.490.1040.105  Disease stage IIHGF receptor0.010.000.270.0090.009EGFR0.290.051.590.1550.156GDF-150.870.521.460.6060.599MIC-A1.100.452.700.8280.827CXCL100.750.401.390.3590.346IL-61.200.841.730.3120.333SCF0.840.401.770.6430.649FABP40.850.451.600.6120.609  Disease stage IIIGDF-151.441.131.830.0030.005FABP41.491.052.100.0240.028MIC-A1.841.063.190.0300.024SCF0.570.340.960.0360.047EGFR0.420.161.100.0760.079CXCL100.750.541.040.0820.073IL-61.220.971.540.0830.085HGF receptor0.950.0518.600.9720.972[^3]

Hepatocyte growth factor receptor was the only protein with p.lr \< .05, in disease stage II, with low protein levels associated with higher risk of recurrence ([Figure 3](#f0015){ref-type="fig"}*A*), however in both disease stages as well as in disease stage III only, no trend with disease recurrence could be seen.Figure 3Kaplan Meier curves representing time to recurrence for hepatocyte growth factor receptor (HGF receptor) disease stages II (3a), growth differentiation factor 15 (GDF-15) disease stages III (3b) and fatty acid-binding protein, adipocyte (FABP4) disease stages III (3c) and C-X-C motif chemokine (CXCL10) III disease stages (3d).Figure 3

In disease stage III only growth differentiation factor 15 (GDF-15) had p.lr \< .01 ([Figure 3](#f0015){ref-type="fig"}*B*), and fatty acid-binding protein, adipocyte (FABP4) ([Figure 3](#f0015){ref-type="fig"}*C*), MHC class I polypeptide-related sequence A (MIC-A) and stem cell factor (SCF) had a p.lr \< .05.

Although not statistically significant in the Cox regression analysis, C-X-C motif chemokine

(CXCL10) had an interesting Kaplan--Meier curve with many early recurrences seen in patients with low CXCL10 levels in disease stage III ([Figure 3](#f0015){ref-type="fig"}*D*).

Combinations of biomarkers according to the description in Materials and Methods did not improve the predictive value of the biomarkers in regard of time to recurrence (data not shown).

Discussion {#s0060}
==========

The present study reveals that there are several soluble protein biomarker candidates of interest in the prediction of survival and disease recurrences in patients with CRC. However, only one protein, osteoprotegerin, did show a statistical significant association with survival.

Overall the biomarker candidates had a stronger non-significant association with overall survival than time to recurrence, which could be due to the fact that there are more endpoints to calculate on when overall survival is used, as the number of deaths exceeds the number of recurrences in this patient cohort. Another explanation could be that the protein expression levels may reflect other conditions leading to death not caused by the CRC or age [@bb0110].

The same observation, with stronger non-significant association of biomarker candidates with prognosis in disease stage III compared with disease stage II, was observed. Also here, an explanation could be that there are more recurrences in disease stage III than in disease stage II, generating more endpoints in disease stage III. A more likely explanation is that disease stage III patients do already have more disseminated disease, generating higher levels of these proteins from the tumor itself, or due to the response of the immune system.

Osteoprotegerin was the only protein with a significant association with overall survival after correction for age and disease stage. This association was found to be strongest in disease stage III. However, it could not be associated with disease recurrence. As the name indicates, osteoprotegerin is a protein with a role in bone homeostasis; it is also named as tumor necrosis factor receptor superfamily member 11B (TNFRSF11B). The difference between osteoprotegerin and the other members of the TNF receptor family is its lack of a trans membrane domain, resulting in osteoprotegerin acting as a decoy receptor, neutralizing TNF-related apoptosis inducing ligand function by binding to it [@bb0115]. The protein inhibits apoptosis by binding to cell death receptors 4 and 5 [@bb0115], [@bb0120] and is in CRC cells regulated by β-catenin [@bb0125]. Expression of osteoprotegerin has been demonstrated to be involved in distant metastases in previous studies [@bb0115], [@bb0130], [@bb0135]. Using immunohistochemical analysis of tumor tissues, it has been demonstrated that overexpression of osteoprotegerin is associated with recurrence of CRC [@bb0115]. The protein has also been studied as a potential target for treatment of CRC with antibodies that antagonize osteoprotegerin, thus increasing tumor cell sensitivity to TNF-related apoptosis inducing ligand, and has successfully been used in animal models to treat tumor-induced bone disease [@bb0115], [@bb0120]. One study has revealed that high serum levels of osteoprotegerin in patients with stage IV CRC was associated with poor prognosis [@bb0140] and one clinical trial has reported the use of osteoprotegerin construct in the treatment of cancer patients [@bb0145]. Increase in osteprotegerin during neoadjuvant therapy for advanced rectal cancer has on the other hand been associated with better progression free survival [@bb0150].

It is more likely that the protein biomarkers are related to the tumor disease itself if a prognostic effect is seen in time to recurrence than overall survival only [@bb0155]. Using correction for multiple comparisons none of the biomarker candidates did meet the *P*-value threshold set by the Bonferroni method. However there are some proteins worth of mention showing a trend of association with recurrence.

GDF-15 is a biomarker studied previously on the present cohort using immunohistochemistry on the primary tumor, which revealed that moderate to high staining intensity was related to higher risk for recurrences compared with none or low staining intensity [@bb0070]. In the present study GDF-15 was related to recurrence in disease stages II and III when analyzed together and in disease stage III when analyzed separately, but not in disease stage II.

In current study, low levels of hepatocyte growth factor receptor, also known as c-MET revealed a trend of higher risk of recurrence in disease stage II, but not in disease stage III or disease stage II and III analyzed together. Increased expression of c-MET measured by immunohistochemistry on the primary tumor is associated with worse prognosis in CRC [@bb0160]. C-MET inhibitors are now used in clinical trial as a therapeutic agent against several cancer types including CRC [@bb0165].

Another observation from the data presented in this study was that a significant association with age was observed for 32 protein biomarkers. This is confirmed by other recent studies, using PEA, demonstrating altered levels of proteins correlated to the age of the individuals [@bb0170], [@bb0175]. Age should therefore be included as a variable in multivariate analysis during survival calculations based on biomarker levels in blood, as was done in the present study. Storage time, storage temperature and sample handling are other factors that may affect the levels of protein abundance [@bb0170], [@bb0180]. The protein measurements were made more than 10 years after the biobanking of the plasma in the present cohort, and it was sampled in a period of 3 years so it is possible that the storage time can affect the protein abundance between the individuals in this cohort.

In this study, Bonferroni\'s method for corrections of multiple testing was used, but in order to not miss potential biomarkers of interest; it was motivated to discuss some of the markers revealing only a trend when it came to the prognostic associations. However, as with all biomarker studies, the results have to be verified by independent cohorts to assure the true value of the findings herein.

Conclusions {#s0065}
===========

Of the 92 analyzed plasma proteins, osteoprotegerin demonstrated the strongest prognostic impact in patients with colorectal cancer, suggesting osteprotegerin as a potential predictive marker and also a plausible target for treatments.
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[^1]: Association of proteins analyzed with PEA with clinical and histopathological parameters, in patients with diseases stage II-IV colorectal cancer, is demonstrated for successful analyses. *P* \< .000107 are marked in bold text

[^2]: Significant associations are marked in bold; the significance threshold is set to 0.05/78 = 0.000641 according to Bonferroni\'s methods for multiple testing correction.

[^3]: HR: hazard ratio, l95: lower 95% confidence interval, p95: upper 95% confidence interval, p.lr: p-value calculated from the likelihood ratio.
